Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Operating Leases (2019 - 2025)

Integra Lifesciences Holdings' Operating Leases history spans 7 years, with the latest figure at $163.1 million for Q4 2025.

  • For Q4 2025, Operating Leases changed N/A year-over-year to $163.1 million; the TTM value through Dec 2025 reached $163.1 million, changed N/A, while the annual FY2025 figure was $163.1 million, N/A changed from the prior year.
  • Operating Leases for Q4 2025 was $163.1 million at Integra Lifesciences Holdings, up from $160.9 million in the prior quarter.
  • Across five years, Operating Leases topped out at $182.1 million in Q4 2023 and bottomed at $90.3 million in Q4 2021.
  • The 5-year median for Operating Leases is $168.8 million (2023), against an average of $161.8 million.
  • The largest annual shift saw Operating Leases surged 74.27% in 2022 before it fell 2.64% in 2024.
  • A 5-year view of Operating Leases shows it stood at $90.3 million in 2021, then soared by 74.27% to $157.4 million in 2022, then rose by 15.7% to $182.1 million in 2023, then dropped by 6.9% to $169.6 million in 2024, then decreased by 3.83% to $163.1 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Operating Leases are $163.1 million (Q4 2025), $160.9 million (Q3 2025), and $173.4 million (Q2 2025).